适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
This is clinical study to test, for the first time in people, the safety (anygood or bad effects), how long the drug can stay in the body and if it cancontrol the disease of people diagnosed with advanced cancer that has notresponded to treatment, has returned after it has been treated, or cannotbe treated by surgery, drugs, or any other known treatments.Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advancedbasal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternativedosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsedand/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104MedDRA version: 23.0Level: PTClassification code: 10029600Term: Non-Hodgkin's lymphoma recurrent Class: 100000004864MedDRA version: 23.0Level: PTClassification code: 10029601Term: Non-Hodgkin's lymphoma refractory Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10012822Term: Diffuse large B-cell lymphoma refractory Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10012821Term: Diffuse large B-cell lymphoma recurrent Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10004146Term: Basal cell carcinoma Class: 100000004864CTIS2023-509969-20-00Celgene Corp.133
进行中（未招募）
1 期
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular diseaseCTIS2024-510878-24-00Cereno Scientific AB48
招募中
1 期
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumoursSolid TumoursCTIS2023-504199-19-00T3 Pharmaceuticals AG100
进行中（未招募）
1 期
A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Trial of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)Amyotrophic Lateral SclerosisMedDRA version: 21.1Level: PTClassification code: 10002026Term: Amyotrophic lateral sclerosis Class: 100000004852CTIS2023-506174-12-00Itb-Med AB48
进行中（未招募）
1 期
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) - targeting, Bifunctional Antibody-fusion molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-Rich (START-001)nresectable, Locally Advanced, or Metastatic Solid TumorsCTIS2023-505334-10-00Marengo Therapeutics Inc.271